OPT Stock - Opthea Limited
Unlock GoAI Insights for OPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $25,000 | $124,666 | $161,163 | $125,047 | $91,981 |
| Gross Profit | $25,000 | $21,720 | $-89,309 | $-107,422 | $-480,000 |
| Gross Margin | 100.0% | 17.4% | -55.4% | -85.9% | -521.8% |
| Operating Income | $-155,762,000 | $-191,842,733 | $-223,449,260 | $-133,270,080 | $-53,179,420 |
| Net Income | $-162,791,000 | $-220,242,105 | $-211,880,680 | $-127,990,214 | $-60,788,020 |
| Net Margin | -651164.0% | -176665.7% | -131469.8% | -102353.7% | -66087.6% |
| EPS | $-1.04 | $-22.16 | $-3.60 | $-2.72 | $-1.44 |
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 25th 2025 | H.C. Wainwright | Downgrade | Neutral | $2 |
| March 25th 2025 | Leerink Partners | Downgrade | Market Perform | $1← $12 |
| March 25th 2025 | Jefferies | Downgrade | Underperform | $1← $8 |
| March 24th 2025 | Oppenheimer | Downgrade | Perform | - |
| December 8th 2022 | H.C. Wainwright | Initiation | Buy | $14 |
| April 26th 2022 | SVB Leerink | Initiation | Outperform | $25 |
Earnings History & Surprises
OPTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q3 2025 | Aug 29, 2025 | $-0.07 | — | — | — |
Q1 2025 | Feb 26, 2025 | $-0.43 | $-1.02 | -137.1% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-0.54 | $-1.23 | -127.8% | ✗ MISS |
Q2 2024 | Apr 11, 2024 | — | $-0.82 | — | — |
Q3 2023 | Sep 12, 2023 | $-1.28 | $-0.64 | +49.9% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.78 | — | — |
Q3 2022 | Aug 29, 2022 | — | $-1.25 | — | — |
Q4 2021 | Dec 31, 2021 | $-0.42 | $-0.80 | -88.9% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | — | $-0.44 | — | — |
Q4 2020 | Dec 31, 2020 | $0.33 | $-0.68 | -307.5% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | — | $-0.10 | — | — |
Q4 2019 | Dec 30, 2019 | $0.00 | $-0.17 | -5634.9% | ✗ MISS |
Q2 2019 | Jun 30, 2019 | — | $-0.13 | — | — |
Q4 2018 | Dec 30, 2018 | — | $-0.28 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.15 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.35 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.14 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.09 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.19 | — | — |
Frequently Asked Questions about OPT
What is OPT's current stock price?
What is the analyst price target for OPT?
What sector is Opthea Limited in?
What is OPT's market cap?
Does OPT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OPT for comparison